https://scholars.lib.ntu.edu.tw/handle/123456789/558310
標題: | Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan | 作者: | Chen J.-F. Peng Y.-S. Chen C.-S. CHIN-HSIAO TSENG Chen P.-C. Lee T.I. Lu Y.-C. Yang Y.-S. Lin C.-L. Hung Y.-J. Chen S.-T. Lu C.-H. Yang C.-Y. Chen C.-C. Lee C.-C. Hsiao P.-J. Jiang J.-Y. Tu S.-T. |
關鍵字: | Dapagliflozin; HbA1c; Real-world evidence; SGLT2 inhibitors; Type 2 diabetes mellitus | 公開日期: | 2020 | 出版社: | PeerJ Inc. | 卷: | 8 | 起(迄)頁: | e9998 | 來源出版物: | PeerJ | 摘要: | Aims/Introduction. To investigate the clinical outcomes of patients with type 2 diabetes mellitus (T2DM) who initiated dapagliflozin in real-world practice in Taiwan. Materials and Methods. In this multicenter retrospective study, adult patients with T2DM who initiated dapagliflozin after May 1st 2016 either as add-on or switch therapy were included. Changes in clinical and laboratory parameters were evaluated at 3 and 6 months. Baseline factors associated with dapagliflozin response in glycated hemoglobin (HbA1c) were analyzed by univariate and multivariate logistic regression. Results. A total of 1,960 patients were eligible. At 6 months, significant changes were observed: HbA1c by ?0.73% (95% confidence interval [CI] ?0.80, ?0.67), body weight was -1.61 kg (95% CI ?1.79, ?1.42), and systolic/diastolic blood pressure by ?3.6/?1.4 mmHg. Add-on dapagliflozin showed significantly greater HbA1c reduction (?0.82%) than switched therapy (?0.66%) (p = 0.002). The proportion of patients achieving HbA1c <7% target increased from 6% at baseline to 19% at Month 6. Almost 80% of patients experienced at least 1% reduction in HbA1c, and 65% of patients showed both weight loss and reduction in HbA1c. Around 37% of patients had at least 3% weight loss. Multivariate logistic regression analysis indicated patients with higher baseline HbA1c and those who initiated dapagliflozin as add-on therapy were associated with a greater reduction in HbA1c. Conclusions. In this real-world study with the highest patient number of Chinese population to date, the use of dapagliflozin was associated with significant improvement in glycemic control, body weight, and blood pressure in patients with T2DM. Initiating dapagliflozin as add-on therapy showed better glycemic control than as switch therapy. Copyright 2020 Chen et al. Distributed under Creative Commons CC-BY 4.0 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096316625&doi=10.7717%2fpeerj.9998&partnerID=40&md5=326a662b84d28bafefc95478d38ef5e1 https://scholars.lib.ntu.edu.tw/handle/123456789/558310 |
ISSN: | 2167-8359 | DOI: | 10.7717/peerj.9998 | SDG/關鍵字: | alpha glucosidase inhibitor; canagliflozin; cholesterol; dapagliflozin; empagliflozin; hemoglobin A1c; high density lipoprotein cholesterol; low density lipoprotein cholesterol; metformin; sodium glucose cotransporter 2 inhibitor; sulfonylurea; triacylglycerol; adult; Article; body mass; body weight; diastolic blood pressure; drug efficacy; female; glycemic control; human; major clinical study; male; middle aged; multicenter study; non insulin dependent diabetes mellitus; observational study; retrospective study; vitamin supplementation |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。